Company profile
Ticker
ACTU
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
SA Recovery Corp., Truli Media Group, Inc., TRULI TECHNOLOGIES, INC.
SEC CIK
Corporate docs
IRS number
473044785
ACTU stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
24 Sep 24
8-K
Changes in Registrant's Certifying Accountant
19 Aug 24
S-8
Registration of securities for employees
14 Aug 24
8-K
Departure of Directors or Certain Officers
14 Aug 24
POS EX
Additional exhibits for listing
13 Aug 24
424B4
Prospectus supplement with pricing info
13 Aug 24
EFFECT
Notice of effectiveness
13 Aug 24
CERT
Certification of approval for exchange listing
12 Aug 24
8-A12B/A
Registration of securities on exchange (amended)
12 Aug 24
FWP
Free writing prospectus
23 Jul 24
Latest ownership filings
4/A
Change in insider ownership (amended)
20 Aug 24
4/A
Aaron G.L. Fletcher
20 Aug 24
4/A
Leslie W. Kreis
20 Aug 24
SC 13D
BIOS Fund I, LP
19 Aug 24
4
TODD S THOMSON
16 Aug 24
4
Change in insider ownership
14 Aug 24
4
Change in insider ownership
14 Aug 24
4
Aaron G.L. Fletcher
14 Aug 24
4
Aaron G.L. Fletcher
14 Aug 24
4
Leslie W. Kreis
14 Aug 24
Financial summary
Quarter (USD) | Jun 24 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 351.71 k | 351.71 k | ||||
Cash burn (monthly) | 1.81 mm | (no burn) | ||||
Cash used (since last report) | 7.22 mm | n/a | ||||
Cash remaining | -6.87 mm | n/a | ||||
Runway (months of cash) | -3.8 | n/a |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Aug 24 | Paul J Lytle | NQSO Common Stock | Grant | Acquire A | No | No | 8 | 234,971 | 1.88 mm | 0 |
14 Aug 24 | Daniel M Schmitt | RSU Common Stock | Grant | Acquire A | No | No | 0 | 544,111 | 0.00 | 0 |
News
Actuate Announces Scientific Reports Publication On Elraglusib's Novel Immunomodulatory Mechanism Of Action As A GSK-3β Inhibitor
23 Sep 24
Actuate Announces Upcoming Presentation On Initial Data On Elraglusib In Combination With FOLFIRINOX At The AACR Special Conference On Advances In Pancreatic Cancer Research
16 Sep 24
Reported Earlier, Actuate Therapeutics Prices $22.4M Initial Public Offering Of 2.8M Common Shares At $8/Share
13 Aug 24
Actuate Therapeutics, Inc To Start Trading Tomorrow
8 Aug 24
Actuate Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know
7 Aug 24
Press releases
Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
23 Sep 24
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
11 Sep 24
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
5 Sep 24
Actuate Therapeutics Announces Closing of Initial Public Offering
14 Aug 24
Actuate Therapeutics Announces Pricing of Initial Public Offering
12 Aug 24